These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34998623)

  • 1. Agreement between a regional pharmacovigilance centre and an adjudication committee regarding adverse drug reactions on a cohort of hospitalised children.
    Pages N; Bounabi A; Boussaha I; Ndiaye M; Portefaix A; Simeon G; Guy C; Stagnara J; Paret N; Vial T; Eftekhari P; Floret D; Gajdos V; Langhendries JP; Bleyzac N; Alberti C; Jacqz-Aigrain E; Nguyen KA; Kassai B;
    Therapie; 2022; 77(4):397-404. PubMed ID: 34998623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between adverse drug reactions and unlicensed/off-label drug use in hospitalized children (EREMI): A study protocol.
    Nguyen KA; Mimouni Y; Jaberi E; Paret N; Boussaha I; Vial T; Jacqz-Aigrain E; Alberti C; Guittard L; Remontet L; Roche L; Bossard N; Kassai B
    Therapie; 2021; 76(6):675-685. PubMed ID: 33593598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inter-rater agreement between WHO- Uppsala Monitoring Centre system and Naranjo algorithm for causality assessment of adverse drug reactions.
    More SA; Atal S; Mishra PS
    J Pharmacol Toxicol Methods; 2024; 127():107514. PubMed ID: 38768933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Reporting Adverse Drug Reactions in Paediatric Patients in a University Hospital in the Netherlands.
    Dittrich ATM; Draaisma JMT; van Puijenbroek EP; Loo DMWMT
    Paediatr Drugs; 2020 Aug; 22(4):425-432. PubMed ID: 32557243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of different methods for causality assessment of adverse drug reactions.
    Behera SK; Das S; Xavier AS; Velupula S; Sandhiya S
    Int J Clin Pharm; 2018 Aug; 40(4):903-910. PubMed ID: 30051231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Causality assessment of adverse drug reactions in neonates: a comparative study between Naranjo's algorithm and Du's tool.
    Leopoldino RWD; de Oliveira LVS; Fernandes FEM; de Lima Costa HTM; Vale LMP; Oliveira AG; Martins RR
    Int J Clin Pharm; 2023 Aug; 45(4):1007-1013. PubMed ID: 37212967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric pharmacovigilance in an institute of national importance: Journey has just begun.
    Sharma PK; Misra AK; Gupta N; Khera D; Gupta A; Khera P
    Indian J Pharmacol; 2017; 49(5):390-395. PubMed ID: 29515280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective identification and causality evaluation of suspected adverse drug reactions in neonates.
    Roberts EK; Hawcutt DB; Turner MA
    Br J Clin Pharmacol; 2021 Mar; 87(3):1541-1546. PubMed ID: 32696451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacovigilance in children in Camagüey Province, Cuba.
    Bárzaga Arencibia Z; López Leyva A; Mejías Peña Y; González Reyes AR; Fernández Manzano E; Choonara I
    Eur J Clin Pharmacol; 2012 Jul; 68(7):1079-84. PubMed ID: 22315149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous Adverse Drug Reaction Monitoring in a Tertiary Care Centre.
    Kaur K; Kanwal P; Goyal P; Singh P; Yakhmi S; Jain S; Kaushal S
    Curr Drug Saf; 2020; 15(3):215-221. PubMed ID: 32735525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of three pharmacovigilance algorithms in the ICU setting: a retrospective and prospective evaluation of ADRs.
    Kane-Gill SL; Forsberg EA; Verrico MM; Handler SM
    Drug Saf; 2012 Aug; 35(8):645-53. PubMed ID: 22720659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved drug safety through intensive pharmacovigilance in hospitalized pediatric patients.
    Vázquez-Alvarez AO; Brennan-Bourdon LM; Rincón-Sánchez AR; Islas-Carbajal MC; Huerta-Olvera SG
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):79. PubMed ID: 29216902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of pattern & distribution of adverse drug reactions in acute coronary syndrome patients in a tertiary care hospital.
    Mahadevappa M; Meher C; Pushpa NB; Kulkarni P; Poornima KS; Desai N
    Indian J Med Res; 2022 Jul; 156(1):111-121. PubMed ID: 36510903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug reactions reported to a provincial public health sector pharmacovigilance programme in South Africa.
    Jones J; Swart A; Tommy E; Cohen K; Stewart A; Voget J; Blockman M
    S Afr Med J; 2020 Nov; 110(12):1226-1230. PubMed ID: 33403970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.
    Blake KV; Zaccaria C; Domergue F; La Mache E; Saint-Raymond A; Hidalgo-Simon A
    Paediatr Drugs; 2014 Aug; 16(4):309-19. PubMed ID: 24898717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does spontaneous adverse drug reactions' reporting differ between different reporters? A study in Toulouse Pharmacovigilance Centre.
    Nicol C; Moulis F; Bondon-Guitton E; Durrieu G; Montastruc JL; Bagheri H
    Therapie; 2019 Oct; 74(5):521-525. PubMed ID: 31029402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
    Awodele O; Aliu R; Ali I; Oni Y; Adeyeye CM
    Pharmacol Res Perspect; 2018 Oct; 6(5):e00427. PubMed ID: 30324768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantifying the Severity of Adverse Drug Reactions Using Social Media: Network Analysis.
    Lavertu A; Hamamsy T; Altman RB
    J Med Internet Res; 2021 Oct; 23(10):e27714. PubMed ID: 34673524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.